These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26456124)

  • 61. Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines.
    Varmeh S; Vanden Borre P; Gunda V; Brauner E; Holm T; Wang Y; Sadreyev RI; Parangi S
    Surgery; 2016 Jan; 159(1):152-62. PubMed ID: 26456124
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
    Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
    Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
    Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
    Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
    Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
    J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
    [TBL] [Abstract][Full Text] [Related]  

  • 65. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
    Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
    Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Integrated genomic characterization of papillary thyroid carcinoma.
    Cancer Genome Atlas Research Network
    Cell; 2014 Oct; 159(3):676-90. PubMed ID: 25417114
    [TBL] [Abstract][Full Text] [Related]  

  • 67. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions.
    Hsu SD; Tseng YT; Shrestha S; Lin YL; Khaleel A; Chou CH; Chu CF; Huang HY; Lin CM; Ho SY; Jian TY; Lin FM; Chang TH; Weng SL; Liao KW; Liao IE; Liu CC; Huang HD
    Nucleic Acids Res; 2014 Jan; 42(Database issue):D78-85. PubMed ID: 24304892
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Deregulation of microRNA expression in thyroid neoplasias.
    Pallante P; Battista S; Pierantoni GM; Fusco A
    Nat Rev Endocrinol; 2014 Feb; 10(2):88-101. PubMed ID: 24247220
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Data, information, knowledge and principle: back to metabolism in KEGG.
    Kanehisa M; Goto S; Sato Y; Kawashima M; Furumichi M; Tanabe M
    Nucleic Acids Res; 2014 Jan; 42(Database issue):D199-205. PubMed ID: 24214961
    [TBL] [Abstract][Full Text] [Related]  

  • 70. BRAF: a driver of the serrated pathway in colon cancer.
    Rustgi AK
    Cancer Cell; 2013 Jul; 24(1):1-2. PubMed ID: 23845435
    [TBL] [Abstract][Full Text] [Related]  

  • 71. MicroRNAs and cancer therapy - from bystanders to major players.
    Braicu C; Calin GA; Berindan-Neagoe I
    Curr Med Chem; 2013; 20(29):3561-73. PubMed ID: 23834177
    [TBL] [Abstract][Full Text] [Related]  

  • 72. BRAF in melanoma: current strategies and future directions.
    Salama AK; Flaherty KT
    Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1.
    Pan YZ; Zhou A; Hu Z; Yu AM
    Drug Metab Dispos; 2013 Oct; 41(10):1744-51. PubMed ID: 23686318
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecular pathogenesis and mechanisms of thyroid cancer.
    Xing M
    Nat Rev Cancer; 2013 Mar; 13(3):184-99. PubMed ID: 23429735
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.
    Montero-Conde C; Ruiz-Llorente S; Dominguez JM; Knauf JA; Viale A; Sherman EJ; Ryder M; Ghossein RA; Rosen N; Fagin JA
    Cancer Discov; 2013 May; 3(5):520-33. PubMed ID: 23365119
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MicroRNA expression profiles in differentiated thyroid cancer, a review.
    Li X; Abdel-Mageed AB; Mondal D; Kandil E
    Int J Clin Exp Med; 2013; 6(1):74-80. PubMed ID: 23236561
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.